Towards personalized treatment for high risk endometrial cancer

Post, C.C.B. (2023)

Doctoral Thesis

This thesis focuses on treatment outcomes of high risk endometrial cancer and corresponding patients’ and clinicians’ preferences regarding adjuvant treatment decisions; molecular studies on the etiology of mismatch repair deficiency (MMRd) in intermediate and high risk endometrial cancer; and the combination of immunotherapy and PARP inhibition for the treatment of recurrent or metastatic endometrial cancer.
The overall aims of this thesis were:
• To evaluate health-related quality of life up to 5 years after chemoradiotherapy compared with pelvic radiotherapy alone in the adjuvant treatment of high risk endometrial cancer in the PORTEC-3 trial;
• To investigate the preferences of patients and clinicians regarding the benefit-risk trade-off of the addition of chemotherapy to adjuvant pelvic radiotherapy;
• To investigate the prevalence and prognosis of Lynch syndrome-associated endometrial cancer among MMRd endometrial cancers;
• To evaluate the role of combined checkpoint inhibition and PARP inhibition in women with metastatic or recurrent endometrial cancer in terms of progression-free survival and toxicity in the DOMEC trial.

• Endometrial Cancer
• Radiotherapy
• Chemotherapy
• Immunotherapy
• PARP inhibition
• Quality of Life
• Sensory Neuropathy
• Mismatch Repair Deficiency
• Lynch Syndrome

• All authors: Post, C.C.B.
• Supervisor: Creutzberg, C.L.
• Co-supervisor: Kroep, J.R.; Bosse, T.
• Committee: Smit, V.H.B.T.M.; Gelderblom, A.J.; Westermann, A.M.; Poll-Franse, L.V. van de; Asperen, C.J. van
• Qualification: Doctor (dr.)
• Awarding Institution: Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University
• Date: 2023-06-13
• ISBN (print): 9789464693225